ABSTRACT
Psoriasis has been associated with increased adiposity measures driving systemic inflammation, which may lead to metabolic dysfunction and comorbidities. In this population-based, cross-sectional study, we used data from 56 042 individuals in the fourth wave of the Trøndelag Health Study (HUNT4), to investigate the associations between psoriasis and body composition measures assessed using bioelectrical impedance analysis, cardiometabolic risk factors, and comorbidities. Further, we investigated the associations between HLA-C*06:02 status, a potential clinical biomarker for a distinct psoriasis endotype, and these outcomes. Psoriasis was associated with increased adiposity measures, including increased body and visceral fat, and lower levels of skeletal muscle and soft lean mass, as well as higher prevalence of cardiovascular, respiratory and endocrine disorders. HLA-C*06:02-positive individuals with psoriasis had lower levels of hsCRP, increased prevalence of atrial fibrillation and decreased prevalence of migraine. Our results point to altered body composition in psoriasis with increased levels of fat, and particularly metabolically active visceral fat, and provide support for a broad clinical approach to psoriatic patients in a general population.
Psoriasis is an immune-mediated, chronic inflammatory skin disease, affecting ∼1-2% of the global population (1). The prevalence of psoriasis differs across nations, and prevalence estimates in Norway are amongst the world’s highest, ranging from 5.8-11.4% (2, 3). Psoriasis arise from a complex interplay between genomics and environmental influences, such as infections, obesity and smoking (4, 5). Observational studies have established and suggested associations between psoriasis and a range of medical conditions including psoriatic arthritis, cardiometabolic, respiratory and endocrine disorders (6, 7). Suggested mechanisms for the associations between psoriasis and comorbidities include shared genetic risk factors, immunologic pathways, vascular endothelial dysfunction and systemic inflammation (8). Common environmental risk factors, including smoking, weight gain and physical inactivity, may also contribute (4, 5). An association between psoriasis and obesity has been established, however, most studies have utilized scales and waist measurements (9). Studies with a more detailed characterization of body composition generally have lower sample sizes (9), with the largest controlled study including 242 individuals with psoriasis. The recent awareness of increased rates of several cardiometabolic risk factors and comorbidities has led attention to closer clinical surveillance and the development of clinical guidelines (7, 10). Several observational studies are based on hospital records. Less is known about the comorbid burden of psoriasis in a general population with higher prevalence estimates of psoriasis including milder cases. In these populations, the best clinical practice is unclear.
Genome-wide association studies have identified >60 loci associated with psoriasis in populations of European descent (11). The HLA-C*06:02 risk allele has been identified as the major genetic contributor (12). HLA-C*06:02-positive individuals tend to have earlier age of psoriasis onset (13) and more severe disease (12, 14). Partial or total remission of psoriasis during pregnancy has been reported in HLA-C*06:02-positive women (14). Further, HLA-C*06:02 could potentially serve as a genetic biomarker of systemic treatment efficacy, as HLA-C*06:02-positive individuals have better response to treatment with ustekinumab and metothrexate (15) and HLA-C*06:02-negative individuals have a better response to adalimumab (16). A recent study found HLA-C*06:02 status to be associated with differences in clinical phenotype and risk of comorbidities, including hypertension, psoriatic arthritis, peptic ulcer, thyroid disease and depression (17). This study also identified sex-specific effects on age of psoriasis onset and adiposity measures. HLA-C*06:02-positive women had earlier disease onset than HLA-C*06:02-positive men and HLA-C*06:02-negative women had higher measures of central adiposity compared to HLA-C*06:02-negative men (17). This makes HLA-C*06:02 a potentially important biomarker of increased risk for more severe disease and altered comorbid burden. The study established HLA-C*06:02-positive individuals as a distinct disease endotype with implications for disease development, burden and treatment (17).
In this study, we aimed to assess the overall prevalence of psoriasis, and to estimate the associations of psoriasis with body composition measures assessed using bioelectrical impedance analysis, cardiometabolic risk factors, and comorbidities in a large population-based study (HUNT4) in Norway. Further we aimed to investigate the recently reported association of HLA-C*06:02 status, anthropometric measures, comorbidities, and for the first time, investigate associations with detailed body composition measurements.
MATERIALS AND METHODS
Study population
The Trøndelag Health Study (HUNT) is an ongoing population-based study, which has collected data in four surveys (18, 19). We used data from HUNT4, carried out in 2017-2019 (18). All inhabitants in the Nord-Trøndelag region aged 20 years or older were invited and 56 042 (54.0%) participated. Participation included extensive questionnaires regarding lifestyle and medical history, non-fasting blood samples and clinical examinations. Participants with missing information regarding psoriasis status were excluded (n = 2669) and the population studied included 53 373 individuals. As some participants had missing information on outcomes, the number of individuals included in each analysis varies. A total of 16 434 individuals were genotyped for rs4406273, of which 931 had psoriasis. For models including genetic information, we excluded non-European and related individuals, leaving a population of 901 psoriatic individuals for analysis.
Classification of psoriasis
Psoriasis was defined as an affirmative response to the following cluster question in HUNT4: “Have you ever had any of the following diseases?” “Psoriasis”. Participants answering no to this question were defined as individuals without psoriasis. The psoriasis question has been validated in the third wave of HUNT (HUNT3) conducted between 2006 and 2008, with a positive predictive value of 78% (2).
Classification of comorbidities
The aforementioned cluster question also included myocardial infarction, angina, cardiac failure, atrial fibrillation, apoplexia, asthma, chronic obstructive pulmonary disorder (COPD), diabetes, hypothyroidism, hyperthyroidism, migraine, renal disease and gout. A positive response to either disease was classified as having that disease. In addition, biochemical measurements were used when available. Diabetes was defined as an affirmative answer and/or an HbA1c ≥ 48 mmol/mol. Hypothyroidism was defined as having an affirmative answer and/or a TSH >4.5 mU/L and free thyroxine <9.0 pmol/L. Hyperthyroidism was defined as an affirmative answer and/or a TSH <0.1 mU/L and free thyroxine >19 pmol/L in individuals without known hypothyroidism. Correspondingly, kidney disease was defined by an affirmative answer and/or an estimated glomerular filtration rate (eGFR) of ≤60 mL/min/1.73 m2.
Clinical examination and laboratory measurements
All clinical examinations were performed by specially trained staff. Blood pressure was measured using Dinamap 845XT based on oscillometry. The average value of the second and third measurement was used. Height and weight were measured with the participants wearing light clothes and no shoes. Body mass index (BMI) was calculated by dividing weight in kilograms by height in meters squared (kg/m2). Body composition of all participants was assessed using bioelectrical impedance analysis, on an InBody 770-instrument (Cerritos, CA, USA). Body composition parameters reported in kilograms (total body fat, skeletal muscle mass, soft lean mass and fat free mass) were reported as a percentage of total body weight. Analyses of non-fasting blood samples were carried out using Architect cSystems ci8200 (Abbott Diagnostics, Longford Ireland).
Genotyping
Genotyping was performed using a custom Illumina HumanCoreExome array (UM HUNT Biobank v.2.0) on 18 722 individuals (20). Ancestry was predicted using principal components of ancestry projected onto the 1000 Genomes Project. Ancestry principal components were generated, and eigen-values were estimated (Supplementary figs. 1 and 2). The single nucleotide polymorphism (SNP) rs4406273 was used as a proxy-SNP for HLA-C*06:02 status, which has shown excellent performance (Matthews correlation coefficient 0.965-1.000) (21). Individuals with psoriasis were classified as either HLA-C*06:02-positive (one or two copies of the rs4406273-A allele) or HLA-C*06:02-negative (no copies).
Statistical analyses
All descriptive variables (except sex) are reported standardized for age applying Stata’s analytic weights option, where observations are weighted inversely proportional to the variance of the observation. Means and 95% confidence intervals (95% CI) were reported for continuous variables and counts and percentages were reported for categorical variables. A generalized linear model was applied to estimate prevalence ratios (PR) for the different outcomes in the psoriatic and non-psoriatic groups. In cases where the model did not converge, we calculated differences in proportion based on predicted mean probabilities from a logistic regression model using Stata’s adjrr command. To adjust for potential confounding in the models, covariates were chosen based on a priori knowledge on disease mechanisms. Two models were constructed; one adjusting for age, sex and BMI and another, fully adjusted model, also adjusting for smoking status, education and alcohol consumption. Subsequently, a sub-analysis was performed among psoriatic individuals, using HLA-C*06:02 status as the exposure and self-reported disease as outcome. The model was adjusted for potential mediators and confounders; age, sex, BMI, smoking status, disease duration and cryptic population structure by four principal components. Precision was assessed by 95% CI. All statistical analyses were conducted using Stata MP v.17.0 (StataCorp, College Station, TX, USA).
Ethics
The study was approved by the Regional Committee for Medical and Health Research Ethics in Central Norway (REK Reference number: 27420), and the Norwegian Data Protection Authority. All HUNT participants gave written informed consent.
RESULTS
Characteristics of the study population
Demographic details of the 53 373 participants are provided in Table I. A total of 3 535 individuals (6.6%) reported psoriasis. Individuals with psoriasis were older, more frequently smokers, and more often HLA-C*06:02-positive than individuals without psoriasis (Table I). The frequency of HLA-C*06:02-positivity was 26.6% among individuals with psoriasis and 11.7% among individuals without psoriasis.
Body composition parameters and cardiometabolic risk factors
Individuals with psoriasis had higher BMI and waist circumference compared to individuals without psoriasis (Table II). They also had higher total body fat (33.3% vs. 31.5%) and visceral fat (138.6 vs. 125.5 cm2), as well as lower levels of skeletal muscle mass (36.8% vs. 37.8%), soft lean mass (62.9% vs. 64.5%) and fat free mass (66.7% vs. 68.5%) (Table II). Females and males contributed equally to these differences (Supplementary table SII). Individuals with psoriasis had higher levels of systolic blood pressure (132.0 vs. 131.1 mmHg), triglycerides (1.8 vs. 1.7 mmol/L), HbA1c (36.4 vs. 35.4 mmol/mol) and high sensitivity CRP (hsCRP) (3.1 vs. 2.7 mg/L) compared to individuals without psoriasis. For systolic blood pressure, this difference was greater in females than in males. HLA-C*06:02- negative psoriatic individuals had a tendency towards higher levels of percentage body fat and visceral fat compared to HLA-C*06:02-positive, with no apparent difference between the sexes (Supplementary table SII). HLA-C*06:02-positive psoriatic individuals had lower levels of hsCRP compared to HLA-C*06:02-negative psoriatic individuals (2.6 vs. 3.3 mg/L) and this difference appeared to sex specific, with the female contribution dominating (Supplementary table SII).
Comorbidities
The prevalence ratios for all comorbidities were adjusted for age and gender, and in the fully adjusted model for age, gender, BMI, smoking and education (Table III). Individuals with psoriasis had higher prevalence of cardiovascular disease, including myocardial infarction (adjusted prevalence ratio (aPR) 1.54) angina pectoris (aPR 1.55), heart failure (aPR 1.56), atrial fibrillation (aPR 1.41) and apoplexia (aPR 1.63) (Table III). The prevalence of asthma (aPR 1.51), COPD (aPR 1.89) diabetes (aPR 1.61), hypothyroidism (aPR 1.32) and hyperthyroidism (aPR 1.58) were higher among individuals with psoriasis. Moreover, the prevalence of migraine (aPR 1.41), renal disease (aPR 1.63) and gout (aPR 1.83) were higher in individuals with psoriasis (Table III). Additional adjustment for BMI, education and smoking reduced the strength of the associations, but they all remained significant.
HLA-C*06:02-positive individuals had higher prevalence of atrial fibrillation (aPR 3.96,) and slightly lower prevalence of migraine (aPR 0.73) compared to HLA-C*06:02-negative individuals (Table IV).
DISCUSSION
In this population-based cross-sectional study, we found a cumulative prevalence for psoriasis of 6.6%. To the best of our knowledge, we have performed the largest study to date evaluating detailed body composition measurements in psoriasis, and confirm previous associations with increased adiposity measures, in particular, metabolically active visceral fat. Our results support previously described associations between psoriasis and increased levels of cardiometabolic risk factors and higher prevalence of a wide range of other medical conditions in individuals with psoriasis. We extend previous studies by investigating associations between detailed body composition measurements, and HLA-C*06:02 status among individuals with psoriasis. HLA-C*06:02-positive individuals had lower percentages of total body fat and visceral fat, lower levels of hsCRP, increased prevalence of atrial fibrillation, and decreased prevalence of migraine.
We found a self-reported prevalence of psoriasis in HUNT4 of 6.6%, which is higher than what has been reported for western Europe (1.9%) (1), but lower than the 11.4% reported in another Norwegian population further north (3). Our results support previous findings of higher rates of psoriasis at higher latitudes (4). Further, the high prevalence in this general population may partly be explained by the identification of milder forms of psoriasis not typically included in hospital-based studies (2).
Adipose tissue can be viewed as an endocrine organ with the capability to induce an inflammatory state through secretion of proinflammatory cytokines including T helper 17 cytokines (9). Inflammatory mediators are suggested to take part in driving the development and worsening of psoriasis and comorbidities (8, 9). Genetically influenced higher BMI has been shown to causally increase the risk of developing psoriasis (5). As adiposity is a potential modifiable risk factor for both psoriasis and several comorbidities, there are important implications of increasing our knowledge of the underlying mechanisms and to evaluate the different types of adiposity independently. Body composition evaluation is superior to the most used metric to classify obesity, namely BMI, as it provides information on lean mass and fat mass distribution, valuable gauges of metabolic health. In addition, body composition assessment using bioelectrical impedance is more sensitive at identifying obesity than BMI (22). Studies have examined the associations between psoriasis and a detailed body compositions, but the results are unclear, potentially due to sample sizes (≤252 individuals with psoriasis) and the use of different assessment modalities across studies (9). Our body composition analyses included 3219 individuals with psoriasis and 45 816 individuals without psoriasis, and we observed that individuals with psoriasis tend to have more body fat, particularly visceral fat, than those without psoriasis. This is corroborated by findings by positron-emission tomography (PET)/computed tomography (CT) in 77 individuals with psoriasis (23) and in a recent systematic review (9).
Visceral adiposity and associated low-grade inflammation have been implicated in the development of a wide range of diseases, including cardiovascular, autoinflammatory, kidney and liver disease (8). HLA-C*06:02-positive psoriatic individuals had lower levels of total body fat and visceral fat than HLA-C*06:02-negative psoriatic individuals. This is in line with previous studies investigating the association between HLA-C*06:02 status and obesity measured by BMI and waist circumference (17). Notably, we also found that HLA-C*06:02- negative women in particular have increased levels of hsCRP, a well-known biomarker of cardiovascular risk. This is in line with previous studies which have found higher prevalence of cardiometabolic risk in women (24), and in particular, HLA-C*06:02-negative women (17). We found that individuals with psoriasis had lower levels of skeletal muscle and soft lean mass by total body weight compared to individuals without psoriasis. Still, despite individuals with psoriasis being on average 2.74 kg heavier than individuals without psoriasis, only 9 g (0.33%) of this difference was made up of muscle mass. Sustained inflammation is shown to give loss of muscle mass and strength (9), and may partly explain the observed low increase in muscle mass relative to increase in body weight.
In recent years, increasing attention has been given towards the association between psoriasis and a wide range of comorbidities. This has proven important to improve quality of life and to reduce the risk of overall mortality among psoriasis patients (25). Aggressive psoriasis treatments may modify cardiovascular mortality rates (26). Further, comorbidities affect the likelihood of achieving systemic treatment response (27). Obesity is shown to give poorer outcomes in biologic treatment efficacy, and a recent US-based study expanded this knowledge to include also other metabolic comorbid conditions at six months (28). To provide specific clinical guidelines for appropriate follow-up, the American Academy of Dermatology (AAD) and the National Psoriasis Foundation (NPF) published Joint Guidelines with recommendations for the management and treatment of comorbidities associated with psoriasis (7). In 2021, the European Academy of Dermatology followed suit (10). However, it has been unclear if knowledge acquired in a hospital-based setting can be applied to a general population with higher prevalence estimates of psoriasis. In the present study, we have provided evidence and replicated associations between psoriasis and a range of cardiovascular diseases (myocardial infarction, angina, heart failure, atrial fibrillation, and apoplexia) (29–31), respiratory diseases (asthma and COPD) (32, 33) and endocrine diseases (diabetes, hypothyroidism, and hyperthyroidism) (34, 35), as well as kidney disease (36), migraine (37) and gout (38). Direct comparison of effect sizes between different studies is difficult due to differences in methodology. However, many studies are based on data on hospitalized patients and may not accurately reflect the burden of disease in a general population. In the present study, associations remain significant after adjusting for age, sex, BMI, education and smoking, however, residual confounding may still occur.
Personalized approaches to treatment and management of psoriasis require the identification of robust biomarkers. Genetic markers may predict certain comorbidities and the effectiveness of treatment, improving patient outcomes. A previous study among psoriasis patients demonstrated that 200 genetic markers were predictive for development of psoriatic arthritis development (area under the receiver operator curve, AUROC = 0.82) (39) and genetic biomarkers can be used to predict treatment efficacy and safety (40). When investigating potential associations between HLA-C*06:02 status and comorbidities in the psoriasis population, we found increased prevalence of atrial fibrillation and decreased prevalence of migraine in HLA-C*06:02-positive individuals. It should be noted that the confidence intervals are wide, and results should therefore be interpreted with caution. In a study of individuals with psoriasis by Douroudis et al., HLA-C*06:02-negativity was associated with higher prevalence of cardiovascular disease and thyroid disease (17), findings which were not replicated in the present study. In the aforementioned study, no significant association between HLA-C*06:02 status and type 2 diabetes or asthma was found (17). In the present study, the samples sizes were too small to meaningfully discuss sex-specific effects of HLA-C*06:02 status on prevalence of comorbidities, as these analyses yielded very wide confidence intervals (Supplementary table IV).
A major strength of this study is the population-based design with a high participation rate of 54.0%. As Norway has one of the world’s highest reported prevalences of psoriasis, studies on Norwegian populations may be of particular interest. To the best of our knowledge, the study is also by far the largest study to date reporting detailed body composition measures in individuals with psoriasis. The use of genetic data in relation to comorbidities contributes to the novelty of this paper as this aspect has sparsely been studied previously. This study did have several limitations. Firstly, we did not investigate subgroups of psoriasis regarding clinical subtype nor severity. In addition, most disease outcomes were self-reported, introducing the possibility of misclassification. However, the psoriasis question in HUNT has previously been validated by experienced dermatologists, with an overall positive predictive value of 78% (2), indicating that self-reported psoriasis in HUNT is a reliable source of data for research purposes. In addition, several of the self-reported variables, including migraine, diabetes, and atrial fibrillation has been validated (18). The present study is at risk of ascertainment bias, wherein individuals with psoriasis are screened for other diseases more frequently than controls due to more frequent contacts with health care services. This may introduce false positive associations between psoriasis and comorbidities.
In conclusion, this large population-based cross-sectional study shows persistently high prevalence of psoriasis in Norway. We have identified increased levels of total body fat and visceral fat, as well as lower levels of skeletal muscle, and soft lean mass in individuals with psoriasis. In addition, we replicated previous findings indicating that HLA-C*06:02-negative individuals, and women in particular, have an increased cardiometabolic risk burden. We also replicated several associations between psoriasis, cardiometabolic risk factors and comorbidities, and identified an increased prevalence of atrial fibrillation and decreased prevalence of migraine in HLA-C*06:02-positive individuals. Our results support the importance of addressing psoriasis as a systemic disease that requires holistic and multidisciplinary care. Special attention should be made towards individuals with psoriasis and obesity and our results highlights the importance of identification of cardiometabolic risk factors and prevention of comorbidities both for the hospital-based dermatologist, as well as for the general practitioner treating these patients in a general population.
Data Availability
Researchers associated with Norwegian research institutes can apply for the use of HUNT data and samples with approval by the Regional Committee for Medical and Health Research Ethics. Researchers from other countries may apply if collaborating with a Norwegian Principal Investigator. Information for data access can be found at https://www.ntnu.edu/hunt/data. The HUNT variables are available for browsing on the HUNT databank at https://hunt-db.medisin.ntnu.no/hunt-db/. Data linkages between HUNT and health registries require that the principal investigator has obtained project-specific approval for such linkage from the Regional Committee for Medical and Health Research Ethics, Norway and each registry owner.
Acknowledgements
We are very grateful to all HUNT participants for donating their time, samples and information to help others and we thank the personnel at the screening surveys. The Trøndelag Health Study (The HUNT Study) is a collaboration between HUNT Research Center (Faculty of Medicine and Health Sciences, NTNU - Norwegian University of Science and Technology), Trøndelag County Council, Central Norway Regional Health Authority, and the Norwegian Institute of Public Health. The genetic investigations of the HUNT Study is a collaboration between researchers from the K.G. Jebsen Center for Genetic Epidemiology and University of Michigan Medical School, and the University of Michigan School of Public Health. The K.G. Jebsen Center for Genetic Epidemiology is financed by Stiftelsen Kristian Gerhard Jebsen; Faculty of Medicine and Health Sciences, NTNU, Norway. ML is supported by grants from the Liaison Committee for education, research and innovation in Central Norway. We thank Marita Jenssen for her suggestions on this manuscript.
Footnotes
Methodology updated to provide accurate company names of instruments used in the study and correct a possible error in the description of the measurement of waist circumference. Results section on comorbidities updated to correct a misinterpretation of data. Updated titles of tables and supplementary tables.
REFERENCES
